Imunon Reports IMNN-001 Clinical Trial Data, OS Median Increased to 14.7 Months

Imunon announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy. The large randomized 112-patient study evaluated IMNN-001 in women with newly diagnosed advanced ovarian cancer. IMNN-001, the company's lead drug candidate, utilizes its proprietary non-viral DNA delivery platform, TheraPlas, the only nucleic acid nanoparticle technology showing promise in treating cancer. This novel immunotherapy is designed to recruit the entirety of the immune system by enabling locoregional secretion of the powerful cancer-fighting cytokine interleukin 12, altering the tumor microenvironment. Based on prior data assessments, IMUNON previously reported a median 11.1-month increase in OS in the IMNN-001 treatment arm compared to SoC chemotherapy alone. Following the most recent data assessment, the company is now reporting a median 14.7-month increase in OS in women in the IMNN-001 treatment arm compared to SoC alone, demonstrating continuous improvement in OS. In addition, the new IMNN-001 data showed that women treated with IMNN-001 and SoC chemotherapy plus poly ADP-ribose polymerase inhibitors as part of maintenance therapy achieved a median increase in OS of 24.2 months compared to SoC chemotherapy alone.